Hot Bank Companies To Invest In 2014

Brent crude oil steadied at $106.50 at 5:31 GMT on Tuesday morning after slipping below $106 on Monday. The commodity has been under pressure as data from China indicated that the number two oil consuming nation's crude appetite waned in 2013.

CNBC reported that preliminary government data showed that Chinese implied oil demand grew just 1.6 percent in 2013. The figure fell short of the International Energy Agency's original prediction of a 3.8 percent rise and weighed on market sentiment.

See also: #PreMarket Primer for January 21: China's Central Bank Adds Record Amounts Of Cash To Market

Top 10 Construction Material Companies To Own For 2015: Capital One Financial Corporation(COF)

Capital One Financial Corporation operates as the bank holding company for the Capital One Bank (USA), National Association (COBNA), and Capital One, National Association (CONA), which provide various financial products and services in the United States, the United Kingdom, and Canada. It offers consumer and small business credit card lending, national closed end installment lending, and the international credit card lending services. The company also provides various non-interest bearing and interest-bearing deposits, including demand deposits, money market deposits, negotiable order of withdrawal accounts, savings accounts, certificates of deposit, and other consumer time deposits. Its loan portfolio comprises credit card loans; consumer loans, such as auto, home, and retail banking loans; and commercial loans, including commercial and multifamily real estate, middle market, specialty lending, and small-ticket commercial real estate loans. In addition, the company provid es mortgage banking, treasury management, and depository services. It primarily serves consumers, small businesses, and commercial clients through branches, the Internet, and other distribution channels. The company was founded in 1993 and is headquartered in McLean, Virginia.

Advisors' Opinion:

• [By Rich Smith]

  In fact, Citi has already made moves in this direction, picking up Best Buy's (NYSE: BBY  ) branded credit card business from Capital One (NYSE: COF  ) earlier this year. Granted, this move seems to contradict Citi's old strategy of lightening up on credit cards, as demonstrated when it unloaded a $1.6 billion credit card portfolio on General Electric (NYSE: GE  ) back in 2010. But that was then, this is now, and today, DTAs are the issue that needs fixing.

Hot Bank Companies To Invest In 2014: Walter Investment Management Corp (WAC)

Walter Investment Management Corp., together with its subsidiaries, is a fee-based business services provider to the residential mortgage industry. The Company is a specialty servicer providing residential loan servicing that focuses on credit-sensitive residential mortgage assets located in the United States. It is also a mortgage portfolio owner and operates an insurance agency serving residential loan customers. The Company operates in four segments: Servicing, Asset Receivables Management (ARM), Insurance, and Loans and Residuals. On July 1, 2011, the Company acquired GTCS Holdings LLC. In November 2012, the Company acquired Reverse Mortgage Solutions, Inc. In January 2013, it acquired originations and capital markets platform of Residential Capital, LLC. In April 2013, the Company announced that its wholly owned subsidiary Reverse Mortgage Solutions, Inc. (RMS) acquired a (Wells Fargo).

Servicing

The Company�� Servicing business segment consists of operations that perform servicing for third-party investors in residential mortgages, manufactured housing and consumer installment loans and contracts, as well as for the Loans and Residuals segment and for the Non-Residual Trusts. During the year ended December 31, 2011, the Company added 259,000 account.

ARM

The Company�� ARM business performs collections of delinquent balances on loans.

Insurance

The Company�� Insurance segment consists of its agency business and its reinsurance businesses. The Company�� Insurance business segment provides voluntary and lender-placed hazard insurance for residential loans, as well as other ancillary products.

Loans and Residuals

The Company's Loans and Residuals business segment consists of the assets and liabilities of the Residual Trusts. It also includes its unencumbered residential loan portfolio and real estate owned.

Advisors' Opinion:

• [By Holly LaFon]

  Despite economic and political turmoil, equity markets performed well across the board in September of 2013 and over the trailing twelve months. The September gains reversed losses in August and also resulted in positive overall quarterly performance with a number of major indexes moving further into record territory. After disturbing the markets in May and June with comments that they may taper Quantitative Easing (QE), the Fed surprised investors with an announcement that it would not reduce its asset purchases in the near-term. The announcement removed fears that a continued rise in interest rates may stall the economic recovery, as seen by the market's negative reaction to the sharp rise in the 10-year Treasury rate in August of 2013. Investors were also comforted by improving fundamentals both domestically and abroad. The Eurozone may finally be emerging from its prolonged recession and a number of economic reports in the U.S. continue to show progress. Specifically, initial unemployment claims dropped to a multiyear low early in September and the housing market continued to improve, as evidenced by prices rising 12.4 percent year-over year, which along with the stock market's strength, has created a positive wealth effect for consumers. In response to this general economic improvement, consumer confidence increased at the end of September, and the index of leading economic indicators ticked up as well, suggesting that, absent the effects of politics, the recovery in the real economy was continuing. Our portfolios that focus on corporate restructuring (Keeley Small Cap Value, Keeley Small-Mid Cap Value, Keeley Mid Cap Value, Keeley All Cap Value, and Keeley Alternative Value) have all experienced a productive investment cycle with respect to their opportunity sets, and many of our holdings have posted impressive results in recent quarters. Although we acknowledge an improving economy has boosted the outlook for our more cyclical holdings, our research has gu

• [By Christina Rexrode]

  Companies like Nationstar have grown tremendously in recent years by buying the rights to service mortgages from big banks. Ben Chittenden, an analyst at Oppenheimer & Co., estimates that Nationstar, Ocwen Financial Corp. (OCN) and Walter Investment Management (WAC) have grown their combined servicing books from $141 billion in the first quarter of 2011 to $1 trillion in the third quarter of 2013.

• [By Amanda Alix]

  An immensely profitable enterprise
  With a line-up of willing sellers -- and free of the capital constraints of banks -- mortgage servicers like Nationstar Mortgage (NYSE: NSM  ) , Ocwen Financial (NYSE: OCN  ) , and Walter Investment (NYSE: WAC  ) have seen their stars rise quickly, experiencing stock price surges of at least 100% over the past year.

• [By Sean Williams]

  What: Shares of Walter Investment Management (NYSE: WAC  ) , a residential mortgage services provider, jumped as much as 12% after the Federal Housing Finance Agency extended the HARP program for two additional years.

Hot Bank Companies To Invest In 2014: Eurobank Ergasias SA (EUROB)

Eurobank Ergasias SA, formerly EFG Eurobank Ergasias SA, is a banking and financial services group located in Greece. It is organized into five segments: Retail, incorporating customer current accounts, savings, deposits and investment savings products, credit and debit cards, consumer loans, small business banking and mortgages; Corporate, incorporating direct debit facilities, current accounts, deposits, overdrafts, loan and other credit facilities, foreign currency and derivative products to corporate entities; Wealth Management, incorporating private banking services, including total wealth management, to medium and high net worth individuals, insurance, mutual fund and investment savings products, and institutional asset management; Global and Capital Markets, incorporating investment banking services including corporate finance, merger and acquisition and equity brokerage, as well as International. On December 27, 2013, it merged by absorption of the New TT Hellenic Postbank SA. Advisors' Opinion:

• [By Corinne Gretler]

  National Bank of Greece surged 24 percent and Eurobank Ergasias SA (EUROB) more than doubled. The lenders��planned merger has been postponed and not canceled, Bank of Greece Governor George Provopoulos said, after statements on April 8 that they will be recapitalized separately.

Hot Bank Companies To Invest In 2014: Independent Bank Group Inc (IBTX)

Independent Bank Group, Inc., incorporated on September 20, 2002, is bank holding company. Through its wholly owned subsidiary, Independent Bank (Bank), a state chartered bank, the Company provides a range of commercial banking products and services for businesses, professionals and individuals. Commercial lending products includes owner-occupied commercial real estate loans, interim construction loans, commercial loans (such as Small Business Administration (SBA) guaranteed loans, business term loans, equipment financing and lines of credit) to a diversified mix of small and midsized businesses, and loans to professionals, particularly medical practices. Retail lending products include residential first and second mortgage loans, and consumer installment loans such as loans to purchase cars, boats and other recreational vehicles. On April 1, 2012, it acquired I Bank Holding Company and its bank subsidiary, and on October 1, 2012, it acquired The Community Group and its bank subsidiary. As of March 18, 2013, it operated 30 banking offices in 26 communities in two market regions located in the Dallas-Fort Worth metropolitan area and in the greater Austin area. Independent Bank operates 30 banking offices throughout North and Central Texas. In December 2013, the Company announced that it has completed the acquisition of Collin Bank, Plano, Texas. In January 2014, Independent Bank Group, Inc. acquired Live Oak Financial Corp. and its subsidiary, Live Oak State Bank.

Lending Activities

Its loans are primarily real estate secured loans spread among a variety of types of borrowers, including owner occupied offices for small businesses, medical practices and offices, retail operations, and multi-family properties. Its loans are diversified geographically throughout its Dallas/North Texas region (approximately 55%) and its Austin/Central Texas region (approximately 45%). As of December 31, 2012, it had total loans of approximately $1.4 billion

The Company is primarily a real es! tate secured lender. It originates real estate loans to finance commercial property that is owner-occupied, as well as commercial property owned by real estate investors. The total amount of owner-occupied commercial real estate loans outstanding as of December 31, 2012, was $353.5 million, or 25.6% of its loan portfolio. The total amount of commercial real estate loans outstanding as of December 31, 2012, excluding owner-occupied properties, was $295 million, or 21.4% of its loan portfolio. The real estate securing its existing commercial real estate loans includes a variety of property types, such as owner-occupied offices/warehouses/production facilities, office buildings, healthcare facilities, hotels, mixed-use residential/commercial, retail centers, multifamily properties, restaurants, churches and assisted living facilities.

The Company�� construction portfolio includes loans to small and midsized businesses to construct owner-user properties, and, to a much lesser extent, loans to developers of commercial real estate investment properties and residential developments. These loans are typically disbursed as construction progresses and carry interest rates that vary with the prime rate. As of December 31, 2012, the outstanding balance of its construction loans was $97.3 million, or 7.1% of its total loan portfolio. It offers first and second mortgage loans to its individual customers primarily for the purchase of primary and secondary residences. As of December 31, 2012, the outstanding balance of one-to four-family real estate secured loans, including home equity loans, represented $315.3 million, or 22.9%, of its total loan portfolio. Residential real estate loans held for sale of $9.2 million at December 31, 2012, were also included in this category.

The Company makes single-family interim construction loans to home builders and individuals to fund the construction of single family residences. Such loans are secured by the real property being built and are made based! on its a! ssessment of the value of the property on an as-completed basis. As of December 31, 2012, the outstanding balance of its single-family interim construction loans was $67.9 million, or 4.9% of its total loan portfolio. The Company originates commercial loans to small businesses and professionals, in particular, medical practices, located in its market areas. These loans are primarily term loans to purchase capital equipment and small loans for working capital and operational purposes. As of December 31, 2012, it had outstanding commercial loans, of $169.9 million, or 12.3% of its total loan portfolio.

The Company�� agricultural loan portfolio primarily includes loans secured by real property used for agricultural purposes. It provides loans for the acquisition of farm and ranch land, as well as the construction of buildings upon agricultural real estate. On a more limited basis, it offers agricultural equipment financing and crop production loans which are secured by crops, equipment, and crop insurance. The total amount of agricultural loans outstanding at December 31, 2012, was $40.1 million, or 2.9% of its total loan portfolio. The Company offers a variety of consumer loans, such as installment loans to purchase cars, boats and other recreational vehicles. Its consumer loans typically are part of an overall customer relationship designed to support the individual consumer borrowing needs of its commercial loan and deposit customers. As of December 31, 2012, it had outstanding $39.5 million of consumer loans, or 2.9% of its total loan portfolio. The Company also engages in the origination of residential loans sold into the secondary market. Its mortgage originations were $177.1 million during the year ended December 31, 2012. It sells all of the originated mortgages to institutional purchasers shortly after closing.

Investment Activities

The types and maturities of securities purchased are primarily based on its liquidity and interest rate sensitivity position! s. As of ! December 31, 2012, investment securities held were United States Treasury securities, government agency securities, obligations of state and municipal subdivisions, Residential mortgage backed securities, and corporate bonds.

Sources of Funds

Deposits are the Company�� principal source of funds for use in lending and other general banking purposes. The Company provides a range of deposit products and services, including a variety of checking and savings accounts, debit cards, online banking, mobile banking, eStatements and bank-by-mail and direct deposit services. It also offers business accounts and management services, including analyzed business checking, business savings, and treasury management services. As of December 31, 2012, it had total deposits of approximately $1.4 billion. In addition to deposits, it utilizes Federal Home Loan Bank (FHLB) advances either as a short-term funding source or a longer-term funding source and to manage its interest rate risks on its loan portfolio. The maximum amount of short-term FHLB advances it had outstanding at any month end during the year ended December 31, 2012, was $16.0 million. The Company�� FHLB borrowings totaled $164.6 million as of December 31, 2012. Its FHLB advances are collateralized by assets, including a blanket pledge of certain loans with a carrying value of $524.8 million and FHLB stock. As of December 31, 2012, it had $92.7 million in undisbursed advance commitments (letters of credit) with the FHLB.

Advisors' Opinion:

• [By Markus Aarnio]

  2. Independent Bank Group (IBTX) operates as a bank holding company for Independent Bank that provides commercial banking products and services for small to medium size businesses, professionals, and individuals in North and Central Texas.

Top 10 Dividend Companies To Own For 2014

After being completely obliterated during the financial crisis, commercial real estate rose sharply in the subsequent years as investors sought the sectors high dividends and values. Overall, real estate investment trusts (REITs) managed to provide investors with a 17.8% annualized return from 2010 through 2012. Those gains continued into the beginning of 2013.

Then the Fed began its tapering talk.

With the potential of rising interest rates on the table, investors have shunned high dividend paying sectors and shares of REITs have plunged in wake of the Fed�� news. Yet, given the commercial real estate sectors long term history of outperformance, investors looking for bargains may want to scoop up shares of operators of shopping plazas, office buildings and hospitals.

SEE: The REIT Way

Better Valuations
After reaching a six-year high set on May 21, 2013, REITs have plunged about 14.75% since the Federal Reserve provided an update regarding its plans for future bond purchases. However, investors may not want to cast off their commercial real estate holdings just yet in the face of the Fed�� taper talk. That�� because REITs continue to offer plenty of portfolio benefits- and time to buy hasn�� been better.

Top 5 Sliver Companies To Own For 2015: JDS Uniphase Corporation(JDSU)

JDS Uniphase Corporation provides communications test and measurement solutions, and optical products for telecommunications service providers, wireless operators, cable operators, network-equipment manufacturers, and enterprises worldwide. The company?s Communications Test and Measurement segment supplies instruments, software, and services to enable the design, deployment, and maintenance of communication equipment and networks. Its product portfolio consists of test tools, platforms, software, and services for wireless and fixed networks. The company?s Communications and Commercial Optical Products segment offers components, modules, subsystems, and solutions that are used by communications equipment providers for telecommunications and enterprise data communications. This segment?s products comprise transmitters, receivers, amplifiers, ROADMs, optical transceivers, multiplexers and demultiplexers, switches, optical-performance monitors and couplers, splitters, and circ ulators, which enable the transmission of video, audio, and text data through fiber-optic cables. It also provides various laser products, including diode, direct-diode, diode-pumped solid-state, fiber, and gas lasers for micromachining, materials processing, bioinstrumentation, consumer electronics, graphics, medical/dental, and optical pumping; and photovoltaic products, such as concentrated photovoltaic cells and receivers for generating energy from sunlight, as well as fiber optic-based systems for delivering and measuring electrical power. The company?s Advanced Optical Technologies segment offers optical solutions for security and brand-differentiation applications; and thin film coatings for a range of public and private-sector markets. This segment also provides multilayer product-security solutions that deliver overt, covert, forensic, and digital product and document verification. JDS Uniphase Corporation was founded in 1979 and is headquartered in Milpitas, Califo rnia.

Advisors' Opinion:

• [By John Divine]

  Shares of�JDS Uniphase (NASDAQ: JDSU  ) lead off today's list, as they cratered 7.3% ahead of what ended up being disappointing earnings. Not only that, but the guidance issued for its next quarter just didn't live up to expectations. That seems to be a theme this earnings season: Even when a company boasts decent results, if future projections aren't up to par, the market will show no mercy.�

• [By FinanceGuru]

  Compelling product and customer base Finisar appears to have one of the broadest product portfolios in the industry. While the firm does have a number of potent competitors, notably JDS Uniphase (JDSU) in the telecom space and Avago (AVGO) in the datacom space, it appears that no other company matches the breadth of Finisar's product offerings across both of these segments.

Top 10 Dividend Companies To Own For 2014: Dominion Resources Inc. (D)

Dominion Resources, Inc., together with its subsidiaries, engages in producing and transporting energy in the United States. It operates in three segments: DVP, Dominion Generation, and Dominion Energy. The DVP segment includes regulated electric transmission and distribution operations that serve residential, commercial, industrial, and governmental customers in Virginia and North Carolina. This segment also involves in non regulated retail energy marketing of electricity and natural gas. The Dominion Generation segment includes the electricity generation through coal, nuclear, gas, oil, and renewables; and related energy supply operations. It also comprises generation operations of the company?s merchant fleet and energy marketing, and price risk management activities for these assets. The Dominion Energy segment includes the company?s Ohio and West Virginia regulated natural gas distribution companies, regulated gas transmission pipeline and storage operations, natural gas gathering and by-products extraction activities, and regulated LNG import and storage operations. It also provides producer services, which aggregates natural gas supply; engages in natural gas trading and marketing activities; and involves in natural gas supply management. The company?s portfolio of assets includes approximately 27,615 MW of generation; 6,100 miles of electric transmission lines; 56,800 miles of electric distribution lines; 11,000 miles of natural gas transmission, gathering, and storage pipeline; and 21,800 miles of gas distribution pipeline. Dominion Resources, Inc. also owns approximately 947 bcf of storage capacity of natural gas and serves retail energy customers in 14 states. In addition, it sells electricity at wholesale prices to rural electric cooperatives, municipalities, and into wholesale electricity markets. The company was founded in 1909 and is headquartered in Richmond, Virginia.

Advisors' Opinion:

• [By David Dittman]

  Question: What do you think is going on with Dominion Resources Inc (NYSE: D) at a price-to-earnings ratio of 72?

  Answer: I was just talking to my colleague Richard Stavros about Dominion’s valuation.

• [By Rich Duprey]

  Padlocking the front gate
  Yet it can't be denied that the demise of many plants has been hastened by the animus against the coal industry. In 2012 alone, Duke Energy (NYSE: DUK  ) retired eight coal plants representing 730 megawatts of capacity and�Dominion (NYSE: D  ) took down nine, eliminating 1.1 gigawatts of capacity. FirstEnergy (NYSE: FE  ) idled three for 500 megawatts.�SourceWatch says two dozen plants will be retired in 2013 representing 2.9 gigawatts of capacity with nearly 50 plants expected to close next year totaling seven gigawatts of capacity.�

Top 10 Dividend Companies To Own For 2014: Reynolds American Inc(RAI)

Reynolds American Inc. (RAI), through its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. It offers cigarettes under the brand names of CAMEL, PALL MALL, WINSTON, KOOL, DORAL, SALEM, MISTY, and CAPRI; and cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand name, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The company also provides smokeless tobacco products, including moist snuff under GRIZZLY and KODIAK brand names; pasteurized tobacco under CAMEL Snus brand name; milled tobacco under the brand name of CAMEL Dissolvables; other tobacco products, such as little cigars under WINCHESTER and CAPTAIN BLACK brand names; and roll-your-own tobacco under the brand name of BUGLER. RAI sells its products primarily through distributors, wholesalers, and other direct customers, including retail chains, as well as distributes its cigarettes to public warehouses. The compan y was founded in 1875 and is headquartered in Winston-Salem, North Carolina.

Advisors' Opinion:

• [By abirk]

  The company undertook strong brand-building initiatives for its Blu eCigs, which included advertisement campaigns on national television, the launch of low-priced rechargeable kits, and expanding the retail distribution network to over 127,000 outlets. Blu e-Cigarettess already have 49% share of the electronic cigarette market in the U.S., which shows potential for future growth. On the other hand, its competitor Reynolds American (RAI)�� leading e-cigarette, Vuse, captures just 2% of the market.

• [By Ben Levisohn]

  Lorillard (LO) has jumped 5.5% to $66.55 after reports that the tobacco company was set to merge–finally–with Reynolds American (RAI). Reynolds American has gained 2.9% to $62.26.

• [By Garrett Cook]

  Shares of Lorillard (NYSE: LO) got a boost, shooting up 4.42 percent to $65.88. Lorillard confirmed that Lorillard and Reynolds American (NYSE: RAI) are engaged in discussions regarding RAI's potential acquisition of Lorillard. Cowen & Company initiated coverage on Lorillard with a Underperform rating.

Top 10 Dividend Companies To Own For 2014: E.I. du Pont de Nemours and Company(DD)

E. I. du Pont de Nemours and Company operates as a science and technology company worldwide. It operates in seven segments: Agriculture & Nutrition, Electronics & Communications, Performance Chemicals, Performance Coatings, Performance Materials, Safety & Protection, and Pharmaceuticals. The Agriculture & Nutrition segment provides hybrid seed corn and soybean seed, herbicides, fungicides, insecticides, value enhanced grains, and soy protein under the Pioneer brand name. The Electronics & Communications segment supplies materials and systems for photovoltaic products, consumer electronics, displays, and advanced printing. The Performance Chemicals segment offers fluorochemicals, fluoropolymers, specialty and industrial chemicals, and white pigments for various markets, such as plastics and coatings, textiles, mining, pulp and paper, water treatment, and healthcare. The Performance Coatings segment supplies high performance liquid and powder coatings for motor vehicle origi nal equipment manufacturers (OEM); the motor vehicle after-market; and general industrial applications, such as such as coatings for heavy equipment, pipes and appliances, and electrical insulation. The Performance Materials segment provides polymers, elastomers, films, parts, and systems and solutions for the automotive OEM and associated after-market industries, as well as electrical, electronics, packaging, construction, oil, photovoltaics, aerospace, chemical processing, and consumer durable goods. The Safety & Protection segment primarily offers nonwovens, aramids, and solid surfaces for the construction, transportation, communications, industrial chemicals, oil and gas, electric utilities, automotive, manufacturing, defense, homeland security, and safety consulting industries. The Pharmaceuticals segment represents its interest in the collaboration relating to Cozaar/Hyzaar antihypertensive drugs. The company was founded in 1802 and is headquartered in Wilmington, Dela ware.

Advisors' Opinion:

• [By Vanina Egea]

  Some say that specializing in one product is the path to success. Others argue that diversifying is a policy against economic recessions. Time has proved that neither strategy is wrong, and that each one has an expiration date. Here are two chemical companies that started with one product and have eventually diversified: DuPont (DD) and Air Products & Chemicals (APD). Let's take a look into their prospects for the years to come.

• [By Matt Thalman]

  Before we hit the Dow losers, let's look at the index's big winner of the week: DuPont (NYSE: DD  ) , which ended the week higher by 7.54% after gaining 4.13% on Tuesday alone. The big move came as the result of DuPont's Q1 results, in which it matched expectations on revenue, beat estimates on earnings per share, and raised its dividend by 5%. The company also reaffirmed its 2013 full-year forecast, which is 2% to 7% higher than what DuPont posted in 2012. �

Top 10 Dividend Companies To Own For 2014: SPX Corporation(SPW)

SPX Corporation provides flow technology products, test and measurement products, thermal equipment and services, and industrial products and services worldwide. The company?s Flow Technology segment provides products and solutions that are used to process, blend, filter, dry, meter, and transport fluids. This segment?s primary offerings include engineered pumps, mixers, process systems, heat exchangers, valves, and dehydration and drying technologies for food and beverage, general industrial, and power and energy markets. Its Test and Measurement segment provides diagnostic service tools, fare-collection systems, and portable cable and pipe locators for the transportation, telecommunications, and utility industries. The company?s Thermal Equipment and Services segment engineers, manufactures, and services cooling, heating, and ventilation products, including dry, wet, and hybrid cooling systems for the power generation, refrigeration, HVAC, and industrial markets, as well as boilers, heating, and ventilation products for the commercial and residential markets. This segment also provides thermal components and engineered services. Its Industrial Products and Services segment designs, manufactures, and markets power systems; industrial tools and hydraulic units; precision machine components for the aerospace industry; crystal growing machines for the solar power generation market; television, radio, and cell phone and data transmission broadcast antenna systems; communications and signal monitoring systems; and precision controlled industrial ovens and chambers. SPX Corporation markets its products through various channels, including stocking distributors, manufacturing representatives, third-party distributors, direct sales, and retailers. The company was formerly known as Piston Ring Company and changed its name to SPX Corporation in 1988. SPX Corporation was founded in 1911 and is headquartered in Charlotte, North Carolina.

Advisors' Opinion:

• [By CRWE]

  SPX Corporation (NYSE:SPW) reported that Jeremy Smeltser, currently transitioning into the CFO role at SPX, will present at the Nomura Inaugural U.S. Industrials Summit in New York City on Wednesday, May 9, 2012 at 12:00 p.m. Eastern time.

• [By Damon Churchwell]

  These companies manufacture processing products used by industries such as food and beverages, oil & gas, and wastewater treatment, among others. They serve a wide range of end markets that are mostly poised for increased earnings and are likely to spend on capital projects. While these positive trends persist, flow technology companies' prospects ought to remain favorable. Let's�highlight several sector participants, starting with a top selection,�SPX�(NYSE: SPW),.

Top 10 Dividend Companies To Own For 2014: UMH Properties Inc.(UMH)

UMH Properties, Inc. (UMH) is a real estate investment trust. The firm engages in the ownership and operation of manufactured home communities. It leases manufactured home spaces to private manufactured home owners, as well as leases homes to residents. The firm invests in the real estate markets of New York, New Jersey, Pennsylvania, Ohio, and Tennessee. In addition, it invests in debt and equity securities of REITs. United Mobile Homes was incorporated in 1968. The company was formerly known as United Mobile Homes, Inc. UMH Properties is based in Freehold, New Jersey.

Advisors' Opinion:

• [By John Udovich]

  Trailer parks may have a bad reputation, but Yahoo! Finance�� Breakout segment was recently touting trailer parks as a hot new investment area���meaning its time for retail investors who don�� want to invest in physical parks to start taking a closer look at trailer park stocks Equity Lifestyle Properties, Inc (NYSE: ELS), Sun Communities Inc (NYSE: SUI) and UMH Properties, Inc (NYSE: UMH). According to the segment, roughly 6% of Americans lived in trailer homes as of 2012 with the�supply of designated trailer parks being quite low because no one wants one in their backyard. Anthony Effinger, the author of another article about trailer parks for Bloomberg, was quoted as saying:

Top 10 Dividend Companies To Own For 2014: Cinemark Holdings Inc(CNK)

Cinemark Holdings, Inc. and its subsidiaries engage in the motion picture exhibition business. As of June 30, 2011, it operated 436 theatres with 4,983 screens in 39 states of the United States, as well as in Brazil, Mexico, and 11 other Latin American countries. The company is headquartered in Plano, Texas.

Advisors' Opinion:

• [By Rich Smith]

  As movie-theater operator Cinemark (NYSE: CNK  ) exits the Mexican market, another "gringo" is expanding to fill the gap -- from even farther north of the border.

• [By John Udovich]

  The shares of small cap IMAX Corporation (NYSE: IMAX) have slipped more than 10% this week on growth concerns - meaning it might be a good idea to take a closer look at the stock plus its performance�verses other cinema stocks like Carmike Cinemas, Inc (NASDAQ: CKEC), Cinemark Holdings, Inc (NYSE: CNK) and Regal Entertainment Group (NYSE: RGC) along with the PowerShares Dynamic Leisure & Entertainment ETF�(NYSEARCA: PEJ).

• [By Teresa Rivas]

  Cinemark Holdings�(CNK) is climbing Tuesday, shaking off earlier weakness as the market digests its better-than-expected second quarter.

  The company said it earned 62 cents a share on revenue of $717.9 million. Analysts were looking for earnings of 48 cents a share on revenue of $707.7 million.

  Average ticket price increased 2.1% in the quarter, and concession revenues per patron grew 2.9%. Admissions overall were $455.7 million while concession sales were $226.5 million.

  FBR�� Barton Crockett reiterated an Outperform rating and $39 price target: ��inemark’s 2Q14 earnings report was encouraging in a difficult period. Revenues beat our expectations on upside in box office per screen growth in Latin America and U.S. concession pricing. Adj. EBITDA beat because of U.S. expenses. Domestically, while Cinemark’s box office trend was in-line with our estimate, it did not feature the Imax/faith-based movie mix headwinds that resulted in underperformance at Regal Entertainment (RGC) and AMC Entertainment (AMC).��/p>

  MKM Partners��� Eric Handler reiterated a Buy rating and $40 price target: ��e look for Cinemark’s shares to outperform the market following better than expected 2Q14 results.�Cinemark beat our/consensus estimates with upside to both domestic and Latin American results. Our positive view towards Cinemark reflects: (1) continued expansion potential of 100-125 screens annually in Latin America; and (2) projected increases in FCF over the next several years, which could lead to more regular dividend increases. The box office will likely remain choppy for the remainder of 2014, but we believe a strong two-year, global content cycle will begin in 2015.��/p>

Top 5 US Companies To Invest In 2014

NEW YORK (AP) — Morningstar says it discovered an illegal intrusion into its systems that may have compromised some of its clients' personal information, including email addresses, passwords, and credit card numbers.

The Investment research provider said the breach took place around April 3.

The intrusion affected about 2,300 users whose credit card information was stored in the Morningstar Document Research system, formerly known as 10-K Wizard. An additional 182,000 clients who had email addresses and user-generated passwords in the system may have been affected, the company said in a filing with the Securities and Exchange Commission.

Morningstar said it shut down old servers and moved data to a more secure system earlier this year in a move unrelated to the incident. It maintains it has taken additional steps to prevent unauthorized access to its systems to protect client information. The company said it is also working with law enforcement officials and credit card companies, as well as investigating the incident on its own.

Top 5 Defense Companies To Buy For 2015: WageWorks Inc (WAGE)

WageWorks, Inc., incorporated on January 28, 2000, is an on-demand provider of tax-advantaged programs for consumer-directed health, commuter and other employee spending account benefits (CDBs), in the United States. The Company administers and operates a broad array of CDBs, including spending account management programs such as health and dependent care Flexible Spending Accounts (FSAs), Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs), and commuter benefits, such as transit and parking programs. The Company delivers its CDB programs through a scalable delivery model that employer clients and their employee participants may access through a standard Web browser on any Internet-enabled device, including computers, smart phones and other mobile devices such as tablet computers. In January 2013, the Company acquired Benefit Concepts, Inc.

The Company focuses on providing CDB programs to employer clients of any size. It provides marketing programs that are designed to maxmize employee participation in its employer clients��CDB offerings. The Company markets and sells its CDB programs through multiple channels, including direct sales to enterprises, direct sales and through brokers to small and medium-sized businesses (SMBs), and direct sales to industry purchasing and affiliate groups and through channel partners.

Its SMB distribution channel complements its enterprise sales channel and consists of third party advisors, including insurance agents and benefits consultants who typically have two to three enterprise clients and several hundred smaller employer clients, and institutional resellers, including regional and national insurance carriers, health plans, payroll providers, commercial banks and third-party administrators (TPAs). The Company also sells its programs through group purchasing organizations in which the Company negotiate a standard service contract with group purchasing organizations that are formed by industry specific employers to cov! er their members.

The Company competes with TASC, Inc, Aetna, UHC, Aon Hewitt, ADP, Ceridian, CDBs and Bank of America.

Advisors' Opinion:

• [By John Udovich]

  On Wednesday, small cap employee flexible spending account facilitator Wageworks Inc (NYSE: WAGE) rose 12.22% despite a secondary offering that effectively rewarded insiders plus the stock has tripled since last March. However, Wageworks��CEO recently said in a�conference call last week that he believes the�private health care exchanges related to Obamacare are expanding�the company���market plus WAGE also raised its forecast for full-year growth. So�does that make this small cap a buy?�

• [By Stock Gamer]

  WageWorks (WAGE) is a leading provider of tax-advantage programs for consumer-directed benefits ("CDBs") in the US. The company operates and administers a wide range of tax-advantage CDBs including health and dependent care Flexible Spending Accounts ("FSAs"), Healthy Savings Accounts ("HSAs"), Health Reimbursement Arrangements ("HRAs"), as well as commuter benefits. WageWorks' CBD programs allow employees to save tax money by using pre-tax earnings to pay for their healthcare and commuter expenses. The programs also enable employers to benefit from reduced payroll taxes as their contributions are deductible for tax purpose, even after factoring in WageWorks' service fees.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on WageWorks (NYSE: WAGE  ) , whose recent revenue and earnings are plotted below.

Top 5 US Companies To Invest In 2014: Direxion Daily Semiconductor Bull 3X Shares (SOXL)

Direxion Daily Semiconductor Bull 3x Shares (the Fund) seeks daily investment results of 300% of the price performance of the PHLX Semiconductor Sector Index (Semiconductor Index). The Semiconductor Index measures the performance of the semiconductor subsector of the United States equity market. Component companies are engaged in the design, distribution, manufacture and sale of semiconductors. As of February 18, 2010, the Semiconductor Index included companies with capitalizations between $1.7 billion and $114 billion. The distributor of the Fund is Foreside Fund Services, LLC. Advisors' Opinion:

• [By John Udovich]

  On Thursday after the market closed, mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) reported earnings and was slipping in after hours trading, meaning its worth taking a closer look at those earnings along with the performance of potential semiconductor benchmarks like the SPDR S&P Semiconductor ETF (NYSEARCA: XSD), iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) and Direxion Daily Semiconductor Bull 3X Shares (NYSEARCA: SOXL). In case you aren�� familiar with the term fabless semiconductor, it�� a�business�model that involves the�outsourcing the manufacturing of silicon wafers.�Most semiconductor companies are actually fabless because of the high cost of building�a facility and manufacturing fab. Therefore, fabless semiconductor companies can�concentrate on the design and marketing of chips while outsourcing the actual production to larger foundry companies.

• [By John Udovich]

  There appears to be light at the end of the tunnel for mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) despite the fact that the company has lost a patent infringement battle with Carnegie Mellon University that could cost it $1.54 billion, meaning its worth taking a closer look at the stock along with the performance of semiconductor ETF benchmarks like SPDR S&P Semiconductor ETF (NYSEARCA: XSD), iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) and Direxion Daily Semiconductor Bull 3X Shares (NYSEARCA: SOXL).

Top 5 US Companies To Invest In 2014: MoneyGram International Inc (MGI)

MoneyGram International, Inc. (MoneyGram) incorporated on December 18, 2003, is a global payment services company. The Company�� products include global money transfers, bill payment solutions and financial paper products. MoneyGram conducts its business through its wholly owned subsidiary MoneyGram Payment Systems, Inc. (MPSI). The Company operates in two segments: Global Funds Transfer and Financial Paper Products. The Company�� global money transfer and bill payment services are its primary revenue drivers. The Company offers its money transfer services on the Internet via its MoneyGram Online service in the United States, United Kingdom and through agent Websites in Italy, Saudi Arabia and Japan. It also offers money transfer services via mobile phone, kiosks, ATM, receive cards and direct-to-bank account products in various markets worldwide. Effective July 8, 2013, MoneyGram International Inc acquired Latino Services, an Atlanta-based provider of money transfer services.

Global Funds Transfer

The Company�� Global Funds Transfer segment provides money transfer and bill payment services to consumers, who are often unbanked or underbanked. Unbanked consumers are those consumers who do not have a traditional relationship with a financial institution. Other consumers who use its services are convenience users and emergency users who may have a checking account with a financial institution, but prefer to use the Company�� services on the basis of convenience or to make emergency payments. MoneyGram offers services to consumers through third-party agents, including retail chains, independent retailers and financial institutions.

The Company provides Global Funds Transfer products and services utilizing a range of point-of-sale platforms. Its platforms include AgentConnect, which is integrated into an agent�� point-of-sale system, and DeltaWorks and Delta T3, which are separate software and stand-alone device platforms. Through its FormFree service, cust! omers may contact its call center and a representative will collect transaction information over the telephone, entering it directly into its central data processing system.

The Company offers money transfers to consumers in a choice of local currency, United States dollars or euros, in certain countries. MoneyGram�� bill payment services allow consumers to make urgent bill payments, pay routine bills, or load and reload prepaid debit cards. These industries include the credit card, mortgage, auto finance, telecommunications, corrections, satellite, property management, prepaid card and collections industries.

Financial Paper Products

The Company�� Financial Paper Products segment provides money orders to consumers through its retail and financial institution agent locations in the United States and Puerto Rico, and provides official check services for financial institutions in the United States. It sells money orders under the MoneyGram brand and on a private label or co-branded basis with certain of its retail and financial institution agents in the United States. During the year ended December 31, 2012, MoneyGram issued money orders through its network of 54,000 agent and financial institution locations in the United States and Puerto Rico. The Company generates revenue from its official check outsourcing services by charging per item and other fees, as well as from the investment of funds underlying outstanding official checks. As of December 31, 2012, the Company also provided official check outsourcing services at approximately 7,300 branch locations of more than 1,200 financial institutions.

The Company competes with The Western Union Company.

Advisors' Opinion:

• [By Lisa Levin]

  Moneygram International (NASDAQ: MGI) shares tumbled 12.29% to touch a new 52-week low of $12.99. JMP Securities downgraded Moneygram from Market Outperform to Market Perform.

• [By Ben Levisohn]

  MoneyGram International�(MGI) has gained 2.8% to $18.94 after it was upgraded to Buy from Neutral at Compass Point.

  U.S. Airways (LCC) has gained 0.2% to $20.53 after it was downgraded to Fair Value from Buy at CRT Capital.

• [By MONEYMORNING.COM]

  "Today, people speculate on the potential," Alex Hoffmann, executive vice president of global product management and emerging channels at MoneyGram International Inc. (NYSE: MGI), told Bloomberg News. "But today you do not have it."

Top 5 US Companies To Invest In 2014: Principal Financial Group Inc(PFG)

Principal Financial Group, Inc. provides retirement savings, investment, and insurance products and services worldwide. The company?s Retirement and Investor Services segment provides retirement savings and related investment products and services, including a portfolio of asset accumulation products and services primarily to small and medium-sized businesses and individuals in the United States. This segment offers products and services to businesses for defined contribution pension plans, including 401(k) and 403(b) plans, defined benefit pension plans, nonqualified executive benefit plans, and employee stock ownership plan consulting services; and annuities, mutual funds, and bank products and services to the employees of its business customers and other individuals. Principal Financial Group?s Principal Global Investors segment offers a range of equity, fixed income, and real estate investments, as well as specialized overlay and advisory services to institutional inve stors. The company?s Principal International segment offers retirement products and services, annuities, mutual funds, institutional asset management, and life insurance accumulation products in Brazil, Chile, China, Hong Kong SAR, India, Indonesia, Malaysia, Mexico, Singapore, and Thailand. Principal Financial Group?s U.S. Insurance Solutions segment offers individual life insurance, as well as specialty benefits in the United States. Its individual life insurance products include universal and variable universal life insurance and traditional life insurance; and specialty benefit products comprise group dental and vision insurance, individual and group disability insurance, and group life insurance, as well as fee-for-service claims administration and wellness services. The company was founded in 1879 and is based in Des Moines, Iowa.

Advisors' Opinion:

• [By Patricio Kehoe] ts newest deal with private benefits company Liazon Corp., through which the firm will offer employer-sponsored group benefit plans to small and medium businesses. While the company already sells ancillary benefit plans, this deal will now also include dental, life insurance, disability insurance and critical illness coverage in an attempt to stay on top of the insurance industry. As an industry leader, Principal has over $466 billion in assets under management and 19 million customers, fragmented among small and medium-size businesses. Furthermore, its solid fourth quarter results have encouraged investment gurus like Paul Tudor Jones (Trades, Portfolio) and Steven Cohen (Trades, Portfolio) to recently acquire large amounts of the company�� shares. So, let�� see what this insurer has in store for the future.

  Broadening Horizons

  Although Principal�� core business is in life insurance, the company has been pursuing a more diverse growth strategy lately, and is now focused on expanding its position in the retirement service and asset management segment. With almost 30,700 pension plans covering over 3.4 million customers, this business��growth rate has not only boosted overall profitability, marked by a 31% annual increase in operating earnings for fiscal 2013, but also helped offset the headwinds of low interest rates and volatility in the emerging markets. In fact, the fourth quarter showed a 65% boost in premium and fee income for the segmenta , consequence of the rollout of total retirement suite products.

  Moreover, Principal�� emphasis on retirement products and its use of capital salesforce for distribution has added on to the natural switching cost advantage in the insurance industry. Since plan sponsors provided with pension assets rarely switch providers, the company will likely benefit in the long term from its persistency, as seen in the quarterly 9% bump in recurring deposits.

  On another note, Principal�� fee-based b

• [By Michael Calia]

  Principal Financial Group Inc.(PFG) said its fourth-quarter earnings rose 8.6%, touting its strong results for the period amid continued economic concern.

10 Best Biotech Stocks For 2014

Over the past two months, the market has mercilessly punished sexy, highly valued stocks. The bloodbath shows yet again that investors ignore the price of a stock at their peril. And despite the plunge in share prices, these former high fliers are still nowhere near bargain levels.

With few exceptions, the companies that took the brunt of the shellacking are involved in either biotechnology or ��ew technology.��Many of them only recently came public. They��e generally involved in businesses everyone is talking about, everything from 3-D printing to cures for hepatitis C.

See also: 5 Scenarios When Selling Stocks Makes Sense

Most hit all-time highs around the end of February��fter big run-ups earlier in the month. Here�� a glimpse at the damage to some of the stocks since March 3: Amazon.com (AMZN), down 17.3%; Dendreon (DNDN), 27.2%; LinkedIn (LNKD), 29.3%; Netflix (NFLX), 26.8%; Plug Power (PLUG), 34.7%; Salesforce.com (CRM), 15.8%; Shutterfly (SFLY), 27.0%; Tesla Motors (TSLA), 17.3%; and Vertex Pharmaceuticals (VRTX), 18.4%. (All returns are through May 6.)

Top Healthcare Equipment Companies To Invest In Right Now: ViroPharma Incorporated(VPHM)

ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; Buccolam, a oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents; and maribavir, an antiviral compound for the treatment o f CMV disease through a license agreement with GlaxoSmithKline. The company?s primary development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; and VP 20621, a non-toxigenic strain of C. difficile. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich?s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.

Advisors' Opinion:

• [By Max Macaluso and David Williamson]

  At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi� (NYSE: SNY  ) may be circling ViroPharma� (NASDAQ: VPHM  ) . The the following video, from The Motley Fool's health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

• [By John Udovich]

  Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ: OMER) and Viropharma Inc (NASDAQ: VPHM) have been active lately thanks to good news about their orphan drug treatments. In case you aren�� familiar with the term, orphan drug designation by the FDA is granted for drugs targeting conditions affecting 200,000 or fewer US patients annually that are expected to provide significant therapeutic advantage over existing treatments. The designation will also qualify companies for benefits across all stages of drug development, such as�accelerated approval processes, seven years of market exclusivity�after marketing approval, tax credits on�any US�clinical trials, grants and waiver of certain administrative fees.

10 Best Biotech Stocks For 2014: Receptos Inc (RCPT)

Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company�� product candidates span three specialty disease areas. The Company�� lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.

As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.

As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company�� second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.

Advisors' Opinion:

• [By John Udovich]

  Small cap �biopharmaceutical stock Receptos Inc (NASDAQ: RCPT) was one of the many hot biotech IPOs of last year and its also up 72.4% since the start of this year alone, meaning its time to take a closer look at this small cap stock with potential treatments for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD) along with the performance of biotech ETF benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).

• [By Roberto Pedone]

  Receptos (RCPT) is a biopharmaceutical company engaged in discovering, developing and commercializing therapeutics for immune disorders. This stock closed up 5% at $23.19 in Monday's trading session.

  Monday's Volume: 69,000
  
  Three-Month Average Volume: 55,356
  
  Volume % Change: 50%

  From a technical perspective, RCPT ripped higher here right above some key near-term support at $21 with decent upside volume. This move is quickly pushing shares of RCPT within range of triggering a major breakout trade. That trade will hit if RCPT manages to take out its all-time high at $25 with high volume.

  Traders should now look for long-biased trades in RCPT as long as it's trending above support at $21 and then once it sustains a move or close above its all-time high at $25 with volume that's near or above 55,356 shares. If that breakout hits soon, then RCPT will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $30 to $35.

• [By RichardCox]

  For those willing to take on some added volatility (and potential for increased risk based on less diversification), investors can look at Receptos Inc. (RCPT), to play this year's momentum in IPO entries. Enhanced expectations for the company's IPO drove the company to raise its initial share offering to 5.2 million shares. Receptos has reached late-stage development for its oral treatment for multiple sclerosis (MS). MS treatments are dominated by industry heavyweights but MS pills are expected to surge in the next few years because oral treatments are becoming more efficient than injected therapies, and can cater to a broader consumer base. Being a new company, the Receptos chart only offers limited incite, and will not be included here.

10 Best Biotech Stocks For 2014: Neurocrine Biosciences Inc.(NBIX)

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Lisa Levin]

  Neurocrine Biosciences (NASDAQ: NBIX) shares moved up 76.95% to $17.27. The volume of Neurocrine Biosciences shares traded was 4406% higher than normal. Neurocrine Biosciences reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

10 Best Biotech Stocks For 2014: Cadus Corp (KDUS)

Cadus Corporation (Cadus), incorporated in January 23, 1992, has a wholly owned subsidiary, Cadus Technologies, Inc. (the Subsidiary), which holds all patents, patent applications, know how, licenses and drug discovery technologies of the Company. The Company maintains all its strains, as well as a biological database that catalogues its collection of cells, cell lines, yeast strains and genetic engineering tools. This database has approximately 30,000 entries, which include the phenotype and the genotype of the cell or yeast strain and its storage site. As of December 31, 2011, the Company had no internal or external drug discovery operations.

Yeast

The Company has developed technologies based on yeast that are useful in identifying drug discovery candidates targeted at G Protein-coupled receptors. Yeast is a single-celled microorganism that is used to make bread, beer and wine. Both yeast and human cells consist of a membrane, an intracellular region and a nucleus containing genes. The genes in yeast express proteins, including cell-surface receptors, such as G Protein-coupled receptors and signaling molecules, such as protein kinases, that are similar to human proteins.

Hybrid Yeast Cells

The Company developed a technology to insert human genes into yeast cells to create hybrid yeast cells. Its scientists created hybrid yeast cells by replacing yeast G Protein-coupled receptor genes and certain signaling molecules with their human equivalents. As a result, these hybrid yeast cells express a human G Protein-coupled receptor and a portion of its signaling pathway. These hybrid yeast cells can be used to identify those compounds that act as agonists or antagonists to that receptor or a molecule that is in its signaling pathway. The Company designed and developed more than 25 thousand genetically different yeast strains that can be used to build hybrid yeast cells (the Yeast System).

The Company competes with Glaxo Smith Kline, Plc.

Advisors' Opinion:

• [By Geoff Gannon] cash producing business like ADDvantage (AEY) that happens to be overcapitalized. I'd much rather own a business with real earnings rather than wait for something to happen with a pile of cash.

  My question is this: How cheap is cheap enough? Clearly (to me), George Risk (RSKIA) is cheap at or even just above book value. It's a darn good business so I'm getting high quality assets and earnings power. That gets less clear when looking at lower quality businesses.

  For example:

  Solitron (SODI) sells at 74% of NCAV, has decent z- and f-scores, a FCF margin of 5.3% and an ROA of 12%.

10 Best Biotech Stocks For 2014: Pain Therapeutics Inc (PTIE)

Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.

REMOXY

REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.

Metastatic Melanoma

The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.

Hemophilia

The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).

Other product candidates

The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.

The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.

Advisors' Opinion:

• [By Sean Williams]

  However, all isn't well when it comes to the future of abuse-resistant painkiller Remoxy, which was developed by Pain Therapeutics (NASDAQ: PTIE  ) , using Durect's�special technology-based gel capsule to prevent abuse, and is licensed by Pfizer (NYSE: PFE  ) . Remoxy has been rejected twice by the FDA -- the most recent coming in mid-2011 -- and Pfizer commented this morning that if it were to seek reapproval for the drug it wouldn't be for at least two more years. Given Pfizer's extensive product pipeline, losing Remoxy wouldn't be a big deal. For micro-cap clinical-stage companies like Pain Therapeutics and Durect, it'd be a gigantic blow. Fittingly, Pain Therapeutics and Durect shares imploded by 50% and 34%, respectively, on Friday.

10 Best Biotech Stocks For 2014: Boston Therapeutics Inc (BTHE)

Boston Therapeutics, Inc. is a development-stage company. The Company�� business is the development, manufacture and commercialization of therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company is focusing on three products: IPOXYN, an injectable anti-hypoxia drug, which it is developing; PAZ320, which is a non-systemic, chewable drug candidate for reduction of blood glucose in diabetics in development and SUGARDOWN, a complex carbohydrate-based chewable dietary supplement, which it is marketing. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the class of carbohydrate-hydrolyzing enzyme inhibitors.

SUGARDOWN

The Company has developed SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement to moderate post-meal blood glucose using processes and technology. It has unrestricted access to both sufficient raw materials at commodity pricing and processing facilities to produce sufficient supply of SUGARDOWN to support product distribution across multiple sales channels as a dietary supplement. Its SUGARDOWN dietary supplement consists of a stabilized complex carbohydrate composition. The Company has completed development of SUGARDOWN as a dietary supplement. On January 24, 2012 the Company announced the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN.

PAZ320

PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes, which release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. PAZ320 is in development as a drug candidate. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the! class of carbohydrate-hydrolyzing enzyme inhibitors.

IPOXYN

The Company has developed a drug candidate product IPOXYN, a glyco-protein based therapeutic agent. Its IPOXYN anti-hypoxia drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. In addition to potential uses for human patients, it also focuses to file a registration for IPOXYN for veterinary applications under the name OXYFEX. The Company�� pharmaceutical agents are intended for intravenous administration into the circulatory system to target acute and late stage diseases.

Advisors' Opinion:

• [By CRWE]

  Today, BTHE remains (0.00%) +0.000 at $1.10 thus far (ref. google finance Delayed: 12:25PM EDT October 10, 2013).

  Boston Therapeutics has previously closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the “Offering”).
  Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease.

10 Best Biotech Stocks For 2014: Lpath Inc (LPTN)

Lpath, Inc. (Lpath), incorporated on September 18, 2002, is a biotechnology company focused on the discovery and development of bio-active lipid-targeted monoclonal antibody (mAb) therapeutics. The Company has three product candidates, iSONEP, ASONEP and Lpathomab. The Company's program, iSONEP, is a mAb against Sphingosine-1-Phosphate (S1P). As of December 31, 2012, it was in phase-II clinical trials for wet Age-Related Macular Degeneration. The Company is also advancing ASONEP, the systemic formulation of the mAb to S1P. ASONEP has completed a phase-I clinical trial and is entering phase-II clinical trials in Renal Cell Carcinoma.

Lpath's third product candidate, Lpathomab, is a mAb to the bioactive lipid, Lysophosphatidic Acid (LPA). The Company also applies its technology platform, ImmuneY2, to discovering mAbs to new bioactive lipid targets.

Advisors' Opinion:

• [By Lauren Pollock]

  Lpath Inc.(LPTN) said it is no longer actively seeking to reacquire exclusive rights to its leading product candidate from Pfizer Inc.(PFE), saying the pharmaceutical giant informed the company that its offers weren’t competitive. The biotechnology company in October had warned that Pfizer might may divest itself of its exclusive option to co-develop the smaller firm’s leading product candidate–known as iSONEP.

Best Rising Companies To Buy For 2014

Today's release of the S&P/Case-Shiller (CSI) home price indices for August reported that the non-seasonally adjusted Composite-10 price index rose a notable 1.33% since July while the Composite-20 index also increased 1.32% over the same period.

The latest CSI data is continuing to demonstrate significant resiliency compared to past years, as prices remained stable through the typically slow winter and early spring period and has been rising notably through the more active spring-summer months.

The 10-city composite index increased 12.75% as compared to August 2012 while the 20-city composite increased 12.82% over the same period.

Both of the broad composite indices still show significant peak declines slumping -21.01% for the 10-city national index and -20.33% for the 20-city national index on a peak comparison basis.

Best Asian Stocks To Invest In 2015: Bell AG (BELL)

Bell AG is a Switzerland-based company that is primarily engaged in the production and distribution of meat. The Company has seven product groups. The Fresh Meat product group is involved in the supply of self-service meat products for the retail trade and products for the restaurant trade, as well as Vaudois specialties. The Charcuterie (own and purchased) product groups offer ready-cooked products, both under the Bell brand and under a number of customers' own brands. The Poultry product group offers various poultry products, as well as specialty meats, such as rabbit, game, ostrich and kangaroo. The Convenience product group offers ready-cooked seasonal convenience products, such as domestic and imported fish. Within the Seafood product group, the Company offers fresh and frozen seafood. Bell AG�� brands include Abraham, Zimbo and Polette, among others. The Company operates subsidiaries in Switzerland, Germany, France, Spain, Belgium, Hungary and other countries. Advisors' Opinion:

• [By Tannor Pilatzke]

  Investment ideas are scarce and hard to come by at times. People constantly ask me about companies they work for (Bell) or businesses they purchase a lot of product from (P&G or Coca-Cola), and what I think about the prospects/valuation. When it is not the blue chips in the limelight it certainly is the Netflix��,Tesla's, 3-D printing, and other companies I would classify as speculative. It is not that I am a Grinch, but I do not like giving out investment ideas. Rather, I attempt to give lessons. As Maimonides said, ��ive a man a fish, feed him for a day; teach a man to fish and feed him for a lifetime.��/p>

Best Rising Companies To Buy For 2014: BankFinancial Corporation(BFIN)

BankFinancial Corporation operates as the holding company for BankFinancial, F.S.B., which provides commercial, family, and personal banking services in Illinois. It accepts deposit accounts, such as savings accounts, NOW accounts, checking accounts, money market accounts, certificates of deposit, and IRAs and other qualified plan accounts. The company?s loan portfolio consists of investment and business loans, including multi-family, nonresidential real estate, commercial, construction and land loans, and commercial leases, as well as one-to-four family residential mortgage loans comprising home equity loans, lines of credit, and other second mortgage loans. It also provides financial products and services consisting of cash management, funds transfers, bill payment and other online banking transactions, automated teller machines, safe deposit boxes, wealth management, and general insurance agency services. In addition, the company offers investment, financial planning, and other wealth management services; and sells life insurance, fixed annuities, property and casualty insurance, and other insurance products on an agency basis. It provides its products and services through banking offices and an Internet Branch. As of December 31, 2009, it operated 18 full-service banking offices and 3 express branch facilities in Cook, DuPage, Lake, and Will Counties, Illinois. The company was founded in 1924 and is headquartered in Burr Ridge, Illinois.

Advisors' Opinion:

• [By Tim Melvin]

  Thompson says the firm likes Bank Financial (BFIN) right now. The bank is in the lucrative Chicago market that has seen a lot of consolidation in the past year. The bank has 20 branches in fairly desirable locations and must be on the target list of anyone looking to expand into Chicago.

Best Rising Companies To Buy For 2014: Japan Petroleum Exploration Co Ltd (JPTXF)

Japan Petroleum Exploration Co., Ltd. is a company principally involved in the energy business. The Company operates in four geological segments. The Japan segment involves in the production, purchase and sale of crude oil and natural gas in Japan, the contracting of drilling and refurbishment works, mud logging works, research works, geophysical exploration works, the provision of pipeline maintenance services and security guard services, the purchase and sale of petroleum products, the transportation of petroleum and natural gas products, as well as real estate management business. The North America segment involves in the exploration and development of crude oil and natural gas in North America. The Middle East segment involves in the development of crude oil and natural gas. The Others segment involves in the exploration, development and production of crude oil and natural gas in Southeast Asia. As of March 31, 2013, the Company had 26 subsidiaries and 17 associated companies. Advisors' Opinion:

• [By WWW.MARKETWATCH.COM]

  LOS ANGELES (MarketWatch) -- Japanese stocks have ended with losses in every session this week, and sure enough, the Nikkei Average (JP:NIK) was down 0.6% in early Friday trade, though off an opening 0.8% defecit, while the Topix carried a 0.7% loss. Overnight losses for the U.S. and further strength in the yen (with the dollar falling to 楼101.28 from 楼101.56 a day earlier) helped drag the market lower, as did results from Fast Retailing Co. (JP:9983) (FRCOF) , the shares of which hold the heaviest weighting on Nikkei Average. Fast Retailing said that while its Uniqlo brand was doing great business, weakness for its J Brand luxury demin label helped send September-May profit down 4% and prompted another cut to Fast's full-year outlook. Consequently, its shares traded 0.7% lower, though rivals Takashimaya Co. (JP:8233) and J. Front Retailing Co. (JP:3086) (JFROF) also saw losses of 0.6% and 0.5%, respectively. Among other decliners, Sony Corp. (JP:6758) (SNE) lost 0.7%, Toshiba Corp. (JP:6502) (TOSYY) fell 2.1%, Kawasaki Heavy Industries Ltd. (JP:7012) (KWHIY) fell 1.5%, Toyota Motor Corp. (JP:7203) (TM) and Nissan Motor Co. (JP:7201)

Best Rising Companies To Buy For 2014: Holly Energy Partners L.P. (HEP)

Holly Energy Partners, L.P. operates a system of petroleum product and crude oil pipelines, storage tanks, distribution terminals, and loading rack facilities. As of December 31, 2009, its pipeline assets included approximately 820 miles of refined product pipelines that transport gasoline, diesel, and jet fuel in the metropolitan and rural areas of Texas, New Mexico, Arizona, Colorado, Utah and northern Mexico; approximately 510 miles of refined product pipelines that transport refined products in Texas and Oklahoma; 3 parallel 65 mile pipelines that transport intermediate feedstocks and crude oil to petroleum refinery facilities; approximately 960 miles of crude oil trunk, gathering, and connection pipelines located in west Texas, New Mexico, and Oklahoma that deliver crude oil to refineries; approximately 10 miles of crude oil and refined product pipelines in Salt Lake City, Utah; and gasoline and diesel connecting pipelines located in Tulsa, Oklahoma. The company?s ref ined product terminals and refinery tankage assets comprised four refined product terminals with an aggregate capacity of approximately 1,000,000 barrels in Texas, New Mexico, and Arizona; three refined product terminals with an aggregate capacity of approximately 500,000 barrels in Idaho and Washington; one refined product terminal with a capacity of 120,000 barrels in Idaho; two refined product terminals with aggregate capacity of 480,000 barrels in Texas; a refined product truck loading rack facility; a jet fuel terminal; on-site crude oil tankage having an aggregate storage capacity of approximately 600,000 barrels; and on-site refined product tankage having an aggregate storage capacity of approximately 1,400,000 barrels. HEP Logistics Holdings, L.P. serves as general partner of the company. Holly Energy Partners was founded in 2004 and is based in Dallas, Texas.

Advisors' Opinion:

• [By Robert Rapier]

  The refinery logistics segment has done quite well, even when the associated refiner has struggled a bit. We like�Holly Energy Partners�(NYSE: HEP) for the long haul. I covered the partnership in some depth in�Holy Holly, What a Deal.

• [By Aimee Duffy]

  Master limited partnerships are not like other stocks, and the metrics we use to compare an MLP to its peers differ from the metrics we use to compare regular companies. For example, instead of the traditional P/E ratio, we emphasize MLP-specific metrics like distribution coverage ratio, and today's focus: price to distributable cash flow (P/DCF). I'll use MPLX (NYSE: MPLX  ) , Tesoro Logistics (NYSE: TLLP  ) , and Holly Energy Partners (NYSE: HEP  ) as our three examples.

Best Rising Companies To Buy For 2014: Hudbay Minerals Inc (HBM)

HudBay Minerals Inc., an integrated mining company, engages in the exploration and development of copper, zinc, and precious metals mines in North and South America. It primarily produces copper concentrates containing copper, gold, and silver; and zinc metal. The company principally owns underground 777 mine that covers an area of 4,400 hectares and is located in Flin Flon, Manitoba. It also owns ore concentrators and a zinc production facility in northern Manitoba and Saskatchewan. The company was founded in 1992 and is based in Toronto, Canada.

Advisors' Opinion:

• [By Dan Caplinger]

  Dan also highlights a new agreement with Brazil's Vale (NYSE: VALE  ) as an example of a new partner streaming agreement that features a focus on gold. Can Silver Wheaton continue to profit from future agreements with partners such as Barrick Gold (NYSE: ABX  ) , Primaro Mining (NYSE: PPP  ) , and Hudbay Minerals (NYSE: HBM  ) ?

Best Rising Companies To Buy For 2014: Regis Corporation(RGS)

Regis Corporation owns, operates, and franchises hairstyling and hair care salons in the United States, the United Kingdom, Canada, Puerto Rico, and internationally. It offers haircutting and styling, including shampooing and conditioning; hair coloring; and waving to men, women, and children. The company also owns and operates hair restoration centers, which provide hair systems, hair transplants, and hair therapy services, as well as hair care products. Its salons operate primarily under the Regis Salons, MasterCuts, SmartStyle, Supercuts, Cost Cutters, Sassoon, Promenade salons, Hair Masters, First Choice Haircutters, Magicuts, and Hair Club trade names in regional shopping malls, strip centers, lifestyle centers, Wal-Mart supercenters, department stores, mass merchants, and high-street locations. As of June 30, 2011, the company owned, franchised, or held ownership interests in approximately 12,700 locations. Regis Corporation was founded in 1922 and is headquartered i n Edina, Minnesota.

Advisors' Opinion:

• [By CRWE]

  Regis Corporation (NYSE:RGS), the global leader in the $160 billion hair care industry, reportedthat it has revised its conference call time on Thursday October 25, 2012. The call will now begin at 4:00pm Central Time. The Company�� financial results for the quarter will be released after the close of the financial markets that day.

• [By Jake L'Ecuyer]

  Regis (NYSE: RGS) shares tumbled 9.13 percent to $12.20 after the company reported downbeat Q2 results.

  Idenix Pharmaceuticals (NASDAQ: IDIX) was down, falling 9.45 percent to $6.61 after JMP Securities downgraded the stock from Market Perform to Market Underperform.

Top Biotech Stocks To Watch For 2014

With the�SPDR S&P Biotech Index�up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies that made waves in the sector last week.

If the biotech sector was to make a movie, I'd have suggested the title be "The Good, the Bad, and the Intriguing" following this week's action.

The good
Leading to the plus column was biotech cancer drug developer Onyx Pharmaceuticals (NASDAQ: ONXX  ) which soared 57% on the week (nearly $50 a share!) after receiving a buyout bid from Amgen�for what amounted to $120 a share. Onyx quickly rebuffed the offer price as too low but did note it was actively looking for strategic alternatives that would properly value Onyx and its pipeline. Earlier in the week I took a deeper dive into Onyx and pegged its fair value at $145 a share. Although I favor the potential of its pipeline, I'm starting to see little upside left in shares at these levels.

Hot Asian Stocks To Invest In Right Now: bluebird bio Inc (BLUE)

bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.

Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.

Adrenoleukodystrophy

Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).

�-thalassemia

�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.

Sickle cell disease

Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.

Advisors' Opinion:

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

Top Biotech Stocks To Watch For 2014: Incyte Corporation(INCY)

Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Advisors' Opinion:

• [By Maxx Chatsko]

  Incite growth into your portfolio
  Investors looking for the next high-growth biotech company should certainly spend time researching Incyte (NASDAQ: INCY  ) . The company sports a handful of the most promising JAK inhibitors, which are garnering high level interest throughout the pharmaceutical industry. The molecules have big potential in treating various cancers and inflammatory diseases such as rheumatoid arthritis and psoriasis.

• [By Ben Levisohn]

  Sure Intercept Pharmaceuticals (ICPT) might feel like the only biotech stock that matters today, but there are others. For instance, Incyte (INCY) and� BioMarin (BMRN) are on the move after Barclays changed its ratings on the pair.

• [By Maxx Chatsko]

  The best part about being a buy-and-hold investor is that when volatility strikes and analysts and pundits are panicking, you can calmly go about your business and steal great companies at bargain prices. One of the stocks on my top watchlist is Incyte (NASDAQ: INCY  ) , which is a growing biotech company focused on developing oncology and anti-inflammatory drugs. The company's shares have recently fallen below $20 for the first time since early February, which I think warrants a deeper look. In the following video, I'll break down the pros and cons of adding Incyte to your portfolio, although I think the company has a lot of potential in its pipeline.

• [By Maxx Chatsko]

  Pfizer will turn its immediate focus to Xeljanz, a novel JAK3 inhibitor, as it awaits phase 3 data from ertugliflozin several years from now. The drug class has swept the pharmaceutical industry by storm. Novartis (NYSE: NVS  ) and Eli Lilly are developing JAK1 and JAK2 inhibitors for several applications with Incyte (NASDAQ: INCY  ) , while a handful of other companies have molecules of their own. While companies have high hopes for the cancer-fighting potential of JAK inhibitors, such as Jakafi from Novartis and Incyte, the biggest opportunities may lie in the immunology market.

Top Biotech Stocks To Watch For 2014: Boston Therapeutics Inc (BTHE)

Boston Therapeutics, Inc. is a development-stage company. The Company�� business is the development, manufacture and commercialization of therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company is focusing on three products: IPOXYN, an injectable anti-hypoxia drug, which it is developing; PAZ320, which is a non-systemic, chewable drug candidate for reduction of blood glucose in diabetics in development and SUGARDOWN, a complex carbohydrate-based chewable dietary supplement, which it is marketing. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the class of carbohydrate-hydrolyzing enzyme inhibitors.

SUGARDOWN

The Company has developed SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement to moderate post-meal blood glucose using processes and technology. It has unrestricted access to both sufficient raw materials at commodity pricing and processing facilities to produce sufficient supply of SUGARDOWN to support product distribution across multiple sales channels as a dietary supplement. Its SUGARDOWN dietary supplement consists of a stabilized complex carbohydrate composition. The Company has completed development of SUGARDOWN as a dietary supplement. On January 24, 2012 the Company announced the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN.

PAZ320

PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes, which release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. PAZ320 is in development as a drug candidate. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the! class of carbohydrate-hydrolyzing enzyme inhibitors.

IPOXYN

The Company has developed a drug candidate product IPOXYN, a glyco-protein based therapeutic agent. Its IPOXYN anti-hypoxia drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. In addition to potential uses for human patients, it also focuses to file a registration for IPOXYN for veterinary applications under the name OXYFEX. The Company�� pharmaceutical agents are intended for intravenous administration into the circulatory system to target acute and late stage diseases.

Advisors' Opinion:

• [By CRWE]

  Today, BTHE remains (0.00%) +0.000 at $1.10 thus far (ref. google finance Delayed: 12:25PM EDT October 10, 2013).

  Boston Therapeutics has previously closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the “Offering”).
  Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease.

Top Biotech Stocks To Watch For 2014: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Advisors' Opinion:

• [By James E. Brumley]

  The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 - a 40% pop - rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that's you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.

• [By James E. Brumley]

  It may look like little more than a choppy mess with just a quick glance at Galena Biopharma Inc. (NASDAQ:GALE). But, the more you study the chart - and the company - the more you realize there's enough long-term potential from the company's pipeline to keep spurring GALE in a generally-upward direction. In fact, the bulls look like they're on the verge of taking Galena Biopharma out of second gear and putting it into third. As such, it may not be a bad bet at this point.

• [By Sean Williams]

  The waiting game
  The tables are clearly stacked against small biotech companies developing cancer drugs. History has shown that few (if any) have successfully had the Food and Drug Administration approve a late-stage cancer drug. While mid-stage trials of Galena Biopharma's (NASDAQ: GALE  ) HER2-targeting breast cancer vaccine have been promising thus far, the chances of an approval seem a long way off.

• [By Paul Ausick]

  Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analyst�� upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.